Evidence map›Paper›PMID 41918959›Full record

ArticleOpen forum infectious diseases2026

Comparing Efficacy and Safety of Itraconazole Solution Versus Posaconazole for Antifungal Prophylaxis After Heart Transplant.

Ralph Tayyar, Darra Drucker, Roy Lee, Thu Le, Jeff Teuteberg, Kiran Khush, Helen Luikart, Tyler Intrieri, Yasbanoo Moayedi, William Alegria and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ralph TayyarDivision of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-5354-0209
Darra DruckerDivision of Pharmacy, Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID https://orcid.org/0009-0008-0350-7532
Roy LeeDepartment of Transplant, Stanford University, Stanford, California, USA.
Thu LeDepartment of Transplant, Stanford University, Stanford, California, USA.
Jeff TeutebergSection of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-8342-3222
Kiran KhushSection of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0001-9697-5926
Helen LuikartSection of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-9782-4449
Tyler IntrieriSection of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California, USA.
Yasbanoo MoayediCardiology, University of Toronto, Toronto, Canada.ORCID https://orcid.org/0000-0002-3288-7393
William AlegriaDivision of Infectious Diseases & Geographic Medicine, Department of Medicine Stanford University School of Medicine Stanford, Stanford, California, USA.
Thomas DieringerDivision of Infectious Diseases & Geographic Medicine, Department of Medicine Stanford University School of Medicine Stanford, Stanford, California, USA.ORCID https://orcid.org/0009-0009-5883-2276
Erik HenricksenDepartment of Transplant, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-4434-584X
Aruna SubramanianDivision of Infectious Diseases & Geographic Medicine, Department of Medicine Stanford University School of Medicine Stanford, Stanford, California, USA.ORCID https://orcid.org/0000-0002-1373-6768

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Posaconazole and itraconazole are 2 oral agents that are commonly prescribed for heart transplant recipients requiring Methods: This was a single-center, retrospective cohort study comparing itraconazole and posaconazole for the prevention of invasive fungal infections in heart transplant recipients between January 2015 and May 2022. The primary efficacy outcome was incidence of fungal infection. The primary safety outcome was incidence of hepatic dysfunction after initiation of therapy. Standard duration of prophylaxis therapy was 3 months for both cohorts. Results: A total of 134 patients received itraconazole prophylaxis and 98 received posaconazole prophylaxis. Patients receiving itraconazole were more likely to have received induction immunosuppression ( Conclusions: Posaconazole prophylaxis after heart transplant was associated with a lower rate of fungal infections and reduced need to change to alternative therapy when compared to itraconazole.

Indexed as

antifungal prophylaxisheart transplantitraconazoleposaconazole

Identifiers

PMID41918959
PMCPMC13034668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.